The Role of Gabapentin in Postoperative Pain and Epithelialization After Photorefractive Keratectomy
Recruitment status was Active, not recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The primary aims of this study are to determine if treatment with Gabapentin taken systemically (oral tablets) in patients who have photorefractive keratectomy (PRK) surgical treatments reduces post surgical neuropathic pain and discomfort. The investigators main Hypothesis is that gabapentin given prior to and after refractive surgery prevents central sensitization and local allodynia.
| Condition | Intervention | Phase |
|---|---|---|
|
Pain After Photorefractive Keratectomy |
Drug: Gabapentin Drug: Sugar pill |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Supportive Care |
| Official Title: | The Role of Gabapentin in Postoperative Pain and Epithelialization After Photorefractive Keratectomy A Prospective, Randomized, Double Blinded, Placebo Controlled Study |
- Pain at moment of examination [ Time Frame: 24 hours postoperatively ] [ Designated as safety issue: No ]
Numerical Visual scale questionnaire. a scale from 0-10 where 0 is the least amount of pain and 10 being the most pain felt was recorded
Every patient will be examined every 24 hours until complete healling which usualy takes place between 3 and 4 days; after complete healing the next and last examination is performed at the 7th postoperative day
- Average pain for the previous 24 hour period, [ Time Frame: assesed at 24 hours ] [ Designated as safety issue: No ]Numerical visual scale questionnaire, a scale from 0-10 where 0 is the least amount of pain and 10 being the most pain felt was recorded
- Maximum pain intensity for the previous 24 hour period [ Time Frame: Assesed at 24 hours postoperatively ] [ Designated as safety issue: No ]In a scale from 0-10 where 0 is the least amount of pain and 10 being the most pain felt was recorded.
- Pain at moment of examination [ Time Frame: 48 hours postoperatively ] [ Designated as safety issue: No ]
Numerical Visual scale questionnaire. a scale from 0-10 where 0 is the least amount of pain and 10 being the most pain felt was recorded
Every patient will be examined every 24 hours until complete healling which usualy takes place between 3 and 4 days; after complete healing the next and last examination is performed at the 7th postoperative day
- pain on examination [ Time Frame: 72 hours postoperatively ] [ Designated as safety issue: No ]
Numerical Visual scale questionnaire. a scale from 0-10 where 0 is the least amount of pain and 10 being the most pain felt was recorded
Every patient will be examined every 24 hours until complete healling which usualy takes place between 3 and 4 days; after complete healing the next and last examination is performed at the 7th postoperative day
- pain on examination [ Time Frame: 96 hours ostoiperatively ] [ Designated as safety issue: No ]
Numerical Visual scale questionnaire. a scale from 0-10 where 0 is the least amount of pain and 10 being the most pain felt was recorded
Every patient will be examined every 24 hours until complete healling which usualy takes place between 3 and 4 days; after complete healing the next and last examination is performed at the 7th postoperative day
- Pain at moment of examination [ Time Frame: postoperative day 7 ] [ Designated as safety issue: No ]
Numerical Visual scale questionnaire. a scale from 0-10 where 0 is the least amount of pain and 10 being the most pain felt was recorded
Every patient will be examined every 24 hours until complete healling which usualy takes place between 3 and 4 days; after complete healing the next and last examination is performed at the 7th postoperative day
- Average pain for the previous 24 hour period [ Time Frame: Assesed at 48 hours ] [ Designated as safety issue: No ]
Numerical Visual scale questionnaire. a scale from 0-10 where 0 is the least amount of pain and 10 being the most pain felt was recorded
Every patient will be examined every 24 hours until complete healling which usualy takes place between 3 and 4 days; after complete healing the next and last examination is performed at the 7th postoperative day
- Average pain during the previous 24 hour period [ Time Frame: Assesed at 72 hours postoperatively ] [ Designated as safety issue: No ]
Numerical Visual scale questionnaire. a scale from 0-10 where 0 is the least amount of pain and 10 being the most pain felt was recorded
Every patient will be examined every 24 hours until complete healling which usualy takes place between 3 and 4 days; after complete healing the next and last examination is performed at the 7th postoperative day
- Average pain for the last 24 hours period [ Time Frame: Assesed at 96 hours postoperatively ] [ Designated as safety issue: No ]
Numerical Visual scale questionnaire. a scale from 0-10 where 0 is the least amount of pain and 10 being the most pain felt was recorded
Every patient will be examined every 24 hours until complete healling which usualy takes place between 3 and 4 days; after complete healing the next and last examination is performed at the 7th postoperative day
- Average pain since last examination [ Time Frame: Assesed on postopertive day 7 ] [ Designated as safety issue: No ]
Numerical Visual scale questionnaire. a scale from 0-10 where 0 is the least amount of pain and 10 being the most pain felt was recorded
Every patient will be examined every 24 hours until complete healling which usualy takes place between 3 and 4 days; after complete healing the next and last examination is performed at the 7th postoperative day
- Maximum pain intensity for the previous 24 hour period [ Time Frame: Assesed at 48 hours postoperatively ] [ Designated as safety issue: No ]
Numerical Visual scale questionnaire. a scale from 0-10 where 0 is the least amount of pain and 10 being the most pain felt was recorded
Every patient will be examined every 24 hours until complete healling which usualy takes place between 3 and 4 days; after complete healing the next and last examination is performed at the 7th postoperative day
- Maximum pain intensity for the previous 24 hour period [ Time Frame: Assesed at 72 hours postoperatively ] [ Designated as safety issue: No ]
Numerical Visual scale questionnaire. a scale from 0-10 where 0 is the least amount of pain and 10 being the most pain felt was recorded
Every patient will be examined every 24 hours until complete healling which usualy takes place between 3 and 4 days; after complete healing the next and last examination is performed at the 7th postoperative day
- Maximum pain intensity for the last 24 hour period [ Time Frame: Assesed at 96 hours postoperatively ] [ Designated as safety issue: No ]
Numerical Visual scale questionnaire. a scale from 0-10 where 0 is the least amount of pain and 10 being the most pain felt was recorded
Every patient will be examined every 24 hours until complete healling which usualy takes place between 3 and 4 days; after complete healing the next and last examination is performed at the 7th postoperative day
- Maximum pain intensity since the last examination [ Time Frame: Assesed on the 7th postoperative day ] [ Designated as safety issue: No ]
Numerical Visual scale questionnaire. a scale from 0-10 where 0 is the least amount of pain and 10 being the most pain felt was recorded
Every patient will be examined every 24 hours until complete healling which usualy takes place between 3 and 4 days; after complete healing the next and last examination is performed at the 7th postoperative day
- Time required for complete healing [ Time Frame: Evaluated each day until complete healing ] [ Designated as safety issue: No ]Slit lamp observation of the epithelial defect and time until removal of contact lens.
- Visual acuity [ Time Frame: every day until complete healing and at the 7th day postop ] [ Designated as safety issue: No ]Snellen Chart
- Foreign body sensation [ Time Frame: Every 24 hours until complete healing and at the 7th day postop ] [ Designated as safety issue: No ]Numerical visual scale, In a scale from 0-10 where 0 is the least amount of foreign body sensation and 10 being the most.
- Light sensitivity [ Time Frame: Every 24 hours until complete healing and at the 7th day postop ] [ Designated as safety issue: No ]Numerical visual scale, in a scale from 0-10 where 0 is the least amount of light sensitibity and 10 being the most.
- Tearing and watery eyes [ Time Frame: Every 24 hours until complete healing and at the 7th day postop ] [ Designated as safety issue: No ]Numerical visual scale questionaire, In a scale from 0-10 where 0 is the least amount of tearing and 10 being the most.
- Eye discomfort [ Time Frame: Every 24 hours until complete healing and at the 7th day postop ] [ Designated as safety issue: No ]Numerical visual scale questionnaire, In a scale from 0-10 where 0 is the least amount of discomfort and 10 being the most.
- Dizziness [ Time Frame: Every 24 hours until complete healling and at the 7th day postop ] [ Designated as safety issue: Yes ]Numerical visual scale, scale from 0-10 where 0 is the least dizzy and 10 being the most.
- lethargy [ Time Frame: Every 24 hours until complete healing and at the 7th day postop ] [ Designated as safety issue: Yes ]Numerical visual scale, In a scale from 0-10 where 0 is the least lethargic and 10 is the most.
- Headache [ Time Frame: Every 24 hours until complete healing and at the 7th day postop ] [ Designated as safety issue: Yes ]Numerical visual scale, In a scale from 0-10 where 0 is the least amount of headache and 10 being the most severe headache felt.
- Gastro-intestinal symptoms [ Time Frame: Every 24 hours until complete healing and at the 7th day postop ] [ Designated as safety issue: Yes ]Numerical visual scale, In a scale from 0-10 where 0 is the least amount of symptoms and 10 being the most symptoms.
| Estimated Enrollment: | 40 |
| Study Start Date: | April 2010 |
| Estimated Study Completion Date: | August 2010 |
| Estimated Primary Completion Date: | July 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: GABAPENTIN
Group of patients treated with oral gabapentin
|
Drug: Gabapentin
Gabapentin PO. (300MG) 1 capsule the night before surgery, q12hrs the day of surgery and q8hrs for the firt 3 postoperative days.
|
|
Placebo Comparator: PLACEBO
Group given the placebo capsules
|
Drug: Sugar pill
Sugar pill. One capsule given the night before surgery, q12hrs on the day of surgery and q8hrs for the first 3 postoperative days.
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subjects must be at least 18 years of age
- Subjects must not have any corneal disease or degeneration
- Subjects must be candidates for LASIK or PRK refractive surgery
Exclusion Criteria:
- History of topical ocular medications within 4 weeks prior to enrollment
- History of conjunctivitis or ocular inflammation within 4 weeks prior to enrollment
- History of a previous refractive surgery
- History of previous diagnosis of corneal disease, degeneration, or glaucoma
- History of autoimmune disease
- History of oral anti-histamines currently or within 1 week of study enrollment
- History of systemic anti-inflammatory or pain medication currently or within 4 weeks of study enrollment
- Use of oral diuretics or betablocker currently or within 1 week of study enrollment
- Current diagnosis of dry eye
- Patients whose Best corrected vision is less than 20/20
- Patients whose target post operative refraction is not plano
- Pregnant and lactating
Contacts and Locations
More Information
No publications provided
| Responsible Party: | Arturo Chayet MD, Codet Vision Institute |
| ClinicalTrials.gov Identifier: | NCT01177514 History of Changes |
| Other Study ID Numbers: | GABA1 |
| Study First Received: | April 23, 2010 |
| Last Updated: | August 10, 2010 |
| Health Authority: | Mexico: Ministry of Health |
Keywords provided by Codet Vision Institute:
|
Refractive surgery PRK PAIN Gabapentin |
Additional relevant MeSH terms:
|
Pain, Postoperative Postoperative Complications Pathologic Processes Pain Signs and Symptoms Gabapentin Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Anticonvulsants |
Antiparkinson Agents Anti-Dyskinesia Agents Calcium Channel Blockers Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Cardiovascular Agents Anti-Anxiety Agents Tranquilizing Agents Central Nervous System Depressants Psychotropic Drugs Excitatory Amino Acid Antagonists Excitatory Amino Acid Agents Neurotransmitter Agents Antimanic Agents |
ClinicalTrials.gov processed this record on May 22, 2013